Related Experiment Videos
Olanzapine: another psychotropic?
1Harry R. Horvitz Center for Palliative Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
The American Journal of Hospice & Palliative Care
|June 16, 2001
Summary
Olanzapine shows potential for treating delirium, psychotic depression, and nausea in advanced cancer patients, offering benefits like weight gain. While costly, reduced hospitalizations may offset expenses.
Area of Science:
- Oncology
- Psychiatry
- Pharmacology
Background:
- Olanzapine is an atypical antipsychotic with potential applications beyond its primary indications.
- Advanced cancer patients often experience complex symptoms including delirium, mood disorders, and nausea.
- Managing these comorbid conditions with a single agent is clinically desirable.
Purpose of the Study:
- To evaluate the potential of olanzapine as a single-agent therapy for multiple conditions in advanced cancer patients.
- To identify the benefits and drawbacks of using olanzapine in this patient population.
Main Methods:
- Literature review of olanzapine's efficacy and safety.
- Analysis of clinical data regarding symptom management in advanced cancer.
Main Results:
- Olanzapine demonstrates potential for treating delirium, psychotic depression, and nausea.
- Weight gain is a noted additional benefit.
- The drug has few interactions but a narrow therapeutic window and high cost.
- A single route of administration is a limitation.
- Potential for reduced hospitalizations may mitigate cost concerns.
Conclusions:
- Olanzapine presents a promising, multi-symptom treatment option for advanced cancer patients.
- Further research is warranted to optimize its use and cost-effectiveness in palliative care.